Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.

about

A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.

P2860

Q39362187-601EF7C3-36B8-42A9-ABA5-747C991B8F57

P2860

Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.

Item

http://www.wikidata.org/entity/Q40234787

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Preclinical development of BCG ...... pecific HIV-1 T-cell immunity.

@en

type

Item

label

Preclinical development of BCG ...... pecific HIV-1 T-cell immunity.

@en

prefLabel

Preclinical development of BCG ...... pecific HIV-1 T-cell immunity.

@en

P1476

Preclinical development of BCG ...... specific HIV-1 T-cell immunity

@en

P2093

Joan Joseph

http://www.w3.org/2001/XMLSchema#string

Josep Ma Gatell

http://www.w3.org/2001/XMLSchema#string

Narcís Saubi

http://www.w3.org/2001/XMLSchema#string

Núria Guitart

http://www.w3.org/2001/XMLSchema#string

Tomáš Hanke

http://www.w3.org/2001/XMLSchema#string

Yoshiki Eto

http://www.w3.org/2001/XMLSchema#string

P2860

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

Modification of the mycobacteriophage Ms6 attP core allows the integration of multiple vectors into different tRNAala T-loops in slow- and fast-growing mycobacteria.

Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.

T-cell function in newborn mice and humans.

Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.

Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen

P304

1798-1810

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2017.1316911

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Aakash Mahant

P577

2017-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28426273

http://www.w3.org/2001/XMLSchema#string

P932

5557246

http://www.w3.org/2001/XMLSchema#string

Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.

about

P2860

P2860

Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932